<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00728910</url>
  </required_header>
  <id_info>
    <org_study_id>807965 CNTR</org_study_id>
    <secondary_id>CTRC #1123</secondary_id>
    <nct_id>NCT00728910</nct_id>
  </id_info>
  <brief_title>Combined Effects of Non-statin Treatments on Apolipoprotein A-I Up-Regulation (CENTAUR): A Feasibility Study</brief_title>
  <acronym>CENTAUR</acronym>
  <official_title>Combined Effects of Non-statin Treatments on Apolipoprotein A-I Up-Regulation (CENTAUR): A Feasibility Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators propose to investigate if using a combination of medications that may
      improve cholesterol give additional benefit to that gained from the statin medication,
      Lipitor. It is recommended that patients who meet certain criteria for risk of heart disease
      take a statin medication to improve cholesterol and hopefully reduce risk of heart disease.
      The combination therapy will include Lipitor, Niaspan, and investigational medication (known
      as ABT335) in a class of drugs called fibrates. We are looking to see if and how these three
      medications together might improve risk factors for atherosclerosis and influence HDL
      cholesterol. The study will also look at the safety and any side effects that might be
      associated with this combination of medications.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objectives Summary

      * To investigate whether the progressive addition of a fibrate and niacin to baseline statin
      therapy will improve apolipoprotein A-I kinetics, postprandial lipidemia, and postabsorptive
      lipoproteins and metabolism in adult men and women with atherogenic dyslipidemia.

      Major Efficacy Aims

        -  Objective 1 is to test the hypothesis that the fibrate ABT335 and extended release (ER)
           niacin progressively improve apolipoprotein A-I kinetics when added sequentially to
           baseline therapy with atorvastatin. The key outcomes include the apolipoprotein AI rate
           of catabolism and rate of production.

        -  Objective 2 is to test the hypothesis that the fibrate ABT335 and ER niacin
           progressively improve postprandial lipidemia by oral fat challenge when added
           sequentially to baseline therapy with atorvastatin. Key outcomes include the incremental
           area under the curve for triglycerides and high-density lipoprotein cholesterol.

        -  Objective 3 is to test the hypothesis that the fibrate ABT335 and ER niacin
           progressively improve markers of postabsorptive lipoproteins and metabolism when added
           sequentially to baseline therapy with atorvastatin. Key outcomes include a. fasting
           cholesterol efflux, b. HDL cholesterol, apolipoprotein A-I, and enzymes that remodel
           HDL, c. atherogenic lipoproteins, and d. markers of energy metabolism and e. markers of
           inflammation.

      Additional Aims

      * Objective 4 is to assess tolerability and adverse events when ABT335 and ER niacin are
      added sequentially to atorvastatin. Specifically, we will assess changes in hepatobiliary
      laboratory tests (including incidence of elevation), incidence of symptomatic myalgia, and
      incidence of flushing. On an exploratory basis, we will enhance the flushing evaluation with
      objective and subjective measurements of flushing during inpatient visits.

      Study Design:

      This is an open-label feasibility study of fixed-sequence addition of lipid-altering
      medications, in which comparisons are made to the baseline for each subject. Subjects begin a
      lead-in phase in which they start the study statin (atorvastatin) or switch from previous
      statin therapy to the study statin. Subjects will wash off other excluded lipid-altering
      drugs during the lead-in. Subjects return for the first inpatient visit, where they have
      baseline studies on statin monotherapy. At the end of this visit, subjects are started on
      fibrate therapy (ABT335). They repeat the studies on dual therapy with statin and fibrate,
      and then add niacin (ER niacin). To minimize flushing during chronic treatment, they start
      aspirin 325 mg daily, or titrate to 325 mg if they are taking a lower dose of aspirin (e.g.
      81 mg). Finally, they repeat the studies on triple therapy with statin, fibrate, and
      niacin/aspirin.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <completion_date type="Actual">August 2009</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Apolipoprotein A-I Fractional Catabolic Rate (FCR)</measure>
    <time_frame>4 weeks, 12 weeks and 22 weeks</time_frame>
    <description>After receiving total daily caloric intake over 20 hrs as 20 identical small meals, starting at 0600 hrs, subjects took study medications at 0800 hrs. Five hours after the first meal, i.v. 5,5,5-2H3-L-leucine was administered, followed by a primed-constant infusion at 10 mol/kg body weight per hr for 15 hrs during which 14 blood samples were collected. Isotopic enrichment of leucine in apoA1 band excised from polyacrylamide gel was calculated. Assuming steady state apo A-I metabolism, we used a compartment model to fit data, consisting a precursor compartment (Compartment 1), the plasma leucine pool, an intracellular compartment accounting for apoA1 synthesis and lipoprotein assembly (Compartment 2), and compartments to account for dispositional kinetics of the subfractions including a plasma pool compartment (Compartment 3). The apoA1 FCR corresponds to the rate of irreversible loss of leucine pools from Compartment 3.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apo-A1 Production Rate</measure>
    <time_frame>4 weeks, 12 weeks and 22 weeks</time_frame>
    <description>The apolipoprotein A-I production rate using (5,5,5-2H3-L-leucine) was measured following each of the three study periods i.e following 4 weeks of atorvastatin 10 mg/day, following 8 further weeks of ABT335 135 mg/day added to atorvastatin and following 10 further weeks of ER niacin 2000 mg/day and aspirin 325 mg/day added to atorvastatin+ABT335.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Post-prandial Triglyceride Incremental Area Under the Curve (iAUC)</measure>
    <time_frame>4 weeks, 12 weeks, 22 weeks</time_frame>
    <description>Triglyceride iAUC was measured during an oral fat tolerance test administered after 4 weeks of atorvastatin 10 mg/day , a further 8 weeks of atorvastatin 10mg /day+ABT335 135mg/day and then after a further 10 weeks of atorvastatin 10 mg/day+ABT335 135 mg/day+Niaspan 2000 mg/day. The standardized oral fat load was administered one hour post medication dosing and blood was collected prior to drug dosing, prior to the oral fat load and hourly thereafter for 10 hours (0,1,2,3,4,5,6,7,8,9,10,12 hrs post drug dosing)</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Dyslipidemia</condition>
  <arm_group>
    <arm_group_label>Atorvastatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>atorvastatin 10 mg/day by mouth for a total duration of 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ABT335</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ABT335 135 mg/day by mouth added to atorvastatin for a total duration of at least 8</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ER niacin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ER niacin titrated up to 2 g/day with aspirin 325 mg/day by mouth added to atorvastatin and ABT335 for 10 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <description>10 mg QD for 4 weeks</description>
    <arm_group_label>Atorvastatin</arm_group_label>
    <arm_group_label>ABT335</arm_group_label>
    <arm_group_label>ER niacin</arm_group_label>
    <other_name>Lipitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABT335</intervention_name>
    <description>135 mg QD added to atorvastatin for 8 weeks</description>
    <arm_group_label>ABT335</arm_group_label>
    <arm_group_label>ER niacin</arm_group_label>
    <other_name>Trilipex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ER Niacin</intervention_name>
    <description>2000 mg QD added to atorvastatin and ABT335 for 10 weeks</description>
    <arm_group_label>ER niacin</arm_group_label>
    <other_name>Niaspan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Men/women aged 18-80 years.

          2. Low HDL-C, adjusted for baseline statin use

               1. Not on statin: Men with HDL &lt;= 40 or women with HDL &lt;= 50 mg/dL

               2. On statin: Men with HDL &lt;= 42 or women with HDL &lt;= 52 mg/dL

          3. TG/HDL ratio &gt;= 3.5

          4. Able to understand and agree to informed consent

          5. Women of child-bearing age must test negative on a urine pregnancy test and agree to
             use reliable birth control during the study and for 1 month after last dose of study
             drugs. Reliable methods include oral contraceptives, a barrier method, intrauterine
             device, partner with vasectomy, or abstinence.

          6. Willing to be available for study duration and follow study procedures

        Exclusion Criteria:

          1. Subjects with following lipoprotein disorders:

               1. Patients on high-potency lipid-lowering regimen, defined as two or more
                  prescription lipid-altering medications (excluding fish oils) where one is a
                  high-dose statin (40 mg/day of rosuvastatin, 80 mg/day of other approved
                  statins). Those on combination therapy with a lower statin dose or those taking
                  high-dose statin monotherapy (excluding fish oils) may participate. Patients will
                  switch to atorvastatin 10 mg and/or wash off other lipid medications to
                  participate

               2. LDL &gt; 190 mg/dL

               3. TG &gt; 750 mg/dL or pancreatitis from triglyceridemia, regardless of current TG
                  levels

               4. Dysbetalipoproteinemia (VLDL/TG &gt; 0.3 -AND- TG &gt; 200 mg/dL).

          2. Use of non-statin lipid therapy prior to study initiation is exclusionary if (n.b.
             washout of non-statins is permitted):

               1. Niacin &gt; 250 mg/ day within 6 weeks: Advicor, Niaspan, Niacor, Simcor,
                  Slo-Niacin, or supplemental niacin

               2. Fibrates within 12 weeks: fenofibrate (Antara, Lofibra, Tricor, Triglide),
                  gemfibrozil (Lopid), or clofibrate

               3. Enterically active drugs within 4 weeks: colestipol, cholestyramine, colesevelam,
                  ezetimibe, orlistat.

               4. Red yeast rice during the treatment phase of the study (i.e. must be switched to
                  study statin)

               5. Fish oil &gt; 2 g/day within 4 weeks: Lovaza (n√©e Omacor), numerous supplements

               6. Altered dose of a selective estrogen receptor modulator (SERM) within 4 weeks

          3. Intolerance to statin, fibrate, aspirin, deuterated leucine, or niacin

          4. Contraindications to medications, including chronic muscle disease, history of
             rhabdomyolysis, moderate-severe gout, severe peptic ulcer disease, bleeding disorders,
             and aspirin-sensitive asthma.

          5. Diabetics, or fasting glucose &gt; 110 mg/dL on two different days during screening, or
             use of anti-diabetic medications within 6 weeks of screening visit

          6. Chronic renal insufficiency, nephrotic syndrome, or current serum creatinine &gt; 2.5
             mg/dL, or GFR &lt; 60 mL/min/1.73m2 by the MDRD equation.

          7. Aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase
             (ALP), total bilirubin &gt; 2 X the upper limit of normal (ULN), albumin of &lt; 2.5 mg/dL,
             prothrombin time (PT) &gt; 1.5 X ULN, partial thromboplastin time (PTT) &gt; 1.5 X ULN, or
             current active hepatobiliary disease

          8. Hemoglobin (Hgb) &lt; 10 mg/dL

          9. Weight &lt; 110 lbs

         10. Use of an investigational drug within 6 weeks prior to screening visit

         11. Major surgery within the previous 6 weeks, or anticipated major surgery during course
             of study, or any history of organ transplant

         12. Non-skin malignancy within previous 5 years

         13. Drug abuse within past 3 years, or regular alcohol use &gt;14 drinks/week

         14. Women who are pregnant, plan to conceive, or breast-feed

         15. Any serious or unstable medical or psychological conditions that, in investigator's
             opinion would compromise subject safety or successful participation.

         16. Currently adhering to, planning to adhere to or used within 3 months prior to
             screening, supplements intended for weight loss or adopt diets with aggressive
             carbohydrate restrictions, such as but not limited to Atkins or South Beach diets.

         17. Currently taking Vitamin A supplements (multivitamins allowed)(washout permitted)

         18. Excluded concomitant medications

               1. Immunosuppressants within 2 months prior to screening or are likely to require
                  such treatment during the course of the study

               2. Warfarin.

         19. Disinclination to dairy products (e.g. inviolable dietary restrictions or lactose
             intolerance to an 8oz glass of milk despite lactase supplementation) Lactase
             supplementation is allowed during the study.

         20. Regular consumers of grapefruit juice, or currently taking medications metabolized by
             CYP 3A4 (cyclosporine, itraconazole, ketoconazole, erythromycin, clarithromycin,
             telithromycin, HIV protease inhibitors, and nefazodone)

         21. History of pancreatitis or gallbladder disease

         22. History of coronary heart disease

         23. History of intolerance/adverse reaction to heparin or women who have dysfunctional
             uterine bleeding

         24. Thrombocytopenia at screening

         25. History of intracerebral or significant GI bleed

         26. Subjects doing regular strenuous activity or have a CK &gt; 3x ULN at screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard L Dunbar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CTRC (Clinical Translational Research Center)</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 4, 2008</study_first_submitted>
  <study_first_submitted_qc>August 5, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 6, 2008</study_first_posted>
  <results_first_submitted>November 29, 2012</results_first_submitted>
  <results_first_submitted_qc>January 28, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 29, 2016</results_first_posted>
  <last_update_submitted>January 28, 2016</last_update_submitted>
  <last_update_submitted_qc>January 28, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pennsylvania</investigator_affiliation>
    <investigator_full_name>Richard Dunbar</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Low HDL cholesterol</keyword>
  <keyword>High triglycerides</keyword>
  <keyword>niacin</keyword>
  <keyword>fibrate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin Calcium</mesh_term>
    <mesh_term>Niacin</mesh_term>
    <mesh_term>Niacinamide</mesh_term>
    <mesh_term>Nicotinic Acids</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment lasted from June 2008 until February 2009.</recruitment_details>
      <pre_assignment_details>Subjects washed out of current lipid lowering medications</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Atorvastatin/ABT335/Niaspan</title>
          <description>All participants received atorvastatin 10 mg/day for 4 weeks, followed by sequential addition of ABT335 135 mg/day for 8 weeks, and ER niacin 2000 mg/day for 10 weeks, for a total study duration of 22 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Atorvastatin</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Atorvastatin+ABT335</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Atorvastatin+ABT335+ER Niacin</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group 1</title>
          <description>All participants received atorvastatin 10 mg/day for 4 weeks, followed by sequential addition of ABT335 135 mg/day for 8 weeks, and ER niacin 2000 mg/day for 10 weeks.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47" spread="10.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Apolipoprotein A-I Fractional Catabolic Rate (FCR)</title>
        <description>After receiving total daily caloric intake over 20 hrs as 20 identical small meals, starting at 0600 hrs, subjects took study medications at 0800 hrs. Five hours after the first meal, i.v. 5,5,5-2H3-L-leucine was administered, followed by a primed-constant infusion at 10 mol/kg body weight per hr for 15 hrs during which 14 blood samples were collected. Isotopic enrichment of leucine in apoA1 band excised from polyacrylamide gel was calculated. Assuming steady state apo A-I metabolism, we used a compartment model to fit data, consisting a precursor compartment (Compartment 1), the plasma leucine pool, an intracellular compartment accounting for apoA1 synthesis and lipoprotein assembly (Compartment 2), and compartments to account for dispositional kinetics of the subfractions including a plasma pool compartment (Compartment 3). The apoA1 FCR corresponds to the rate of irreversible loss of leucine pools from Compartment 3.</description>
        <time_frame>4 weeks, 12 weeks and 22 weeks</time_frame>
        <population>Patients who completed any of the three phases for whom the kinetic study data was available for any phase of treatment</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin</title>
            <description>Subjects received atorvastatin 10 mg daily by mouth for 4 weeks followed by apo-A1 kinetics</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin+ABT335</title>
            <description>Subjects received atorvastatin 10 mg daily and ABT335 135 mg daily by mouth for 8 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Atorvastatin+ABT335+Niaspan</title>
            <description>Subjects received atorvastatin 10 mg daily, ABT335 135 mg and Niaspan 2000 mg daily by mouth for 10 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>The Apolipoprotein A-I Fractional Catabolic Rate (FCR)</title>
          <description>After receiving total daily caloric intake over 20 hrs as 20 identical small meals, starting at 0600 hrs, subjects took study medications at 0800 hrs. Five hours after the first meal, i.v. 5,5,5-2H3-L-leucine was administered, followed by a primed-constant infusion at 10 mol/kg body weight per hr for 15 hrs during which 14 blood samples were collected. Isotopic enrichment of leucine in apoA1 band excised from polyacrylamide gel was calculated. Assuming steady state apo A-I metabolism, we used a compartment model to fit data, consisting a precursor compartment (Compartment 1), the plasma leucine pool, an intracellular compartment accounting for apoA1 synthesis and lipoprotein assembly (Compartment 2), and compartments to account for dispositional kinetics of the subfractions including a plasma pool compartment (Compartment 3). The apoA1 FCR corresponds to the rate of irreversible loss of leucine pools from Compartment 3.</description>
          <population>Patients who completed any of the three phases for whom the kinetic study data was available for any phase of treatment</population>
          <units>pools/day</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.294" lower_limit="0.27" upper_limit="0.32"/>
                    <measurement group_id="O2" value="0.294" lower_limit="0.27" upper_limit="0.32"/>
                    <measurement group_id="O3" value="0.295" lower_limit="0.25" upper_limit="0.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis was that the sequential addition of a fibrate and niacin to baseline atorvastatin therapy would not have any effect on apo-AI catabolism.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.5</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Apo-A1 Production Rate</title>
        <description>The apolipoprotein A-I production rate using (5,5,5-2H3-L-leucine) was measured following each of the three study periods i.e following 4 weeks of atorvastatin 10 mg/day, following 8 further weeks of ABT335 135 mg/day added to atorvastatin and following 10 further weeks of ER niacin 2000 mg/day and aspirin 325 mg/day added to atorvastatin+ABT335.</description>
        <time_frame>4 weeks, 12 weeks and 22 weeks</time_frame>
        <population>Patients who completed any phase of treatment for whom kinetic data were available</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin</title>
            <description>Subjects received atorvastatin 10 mg daily by mouth for 4 weeks followed by apo-A1 kinetics</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin+ABT335</title>
            <description>Subjects received atorvastatin 10 mg daily and ABT335 135 mg daily by mouth for 8 weeks.</description>
          </group>
          <group group_id="O3">
            <title>Atorvastatin+ABT335+Niaspan</title>
            <description>Subjects received atorvastatin 10 mg daily, ABT335 135 mg and Niaspan 2000 mg daily by mouth for 10 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Apo-A1 Production Rate</title>
          <description>The apolipoprotein A-I production rate using (5,5,5-2H3-L-leucine) was measured following each of the three study periods i.e following 4 weeks of atorvastatin 10 mg/day, following 8 further weeks of ABT335 135 mg/day added to atorvastatin and following 10 further weeks of ER niacin 2000 mg/day and aspirin 325 mg/day added to atorvastatin+ABT335.</description>
          <population>Patients who completed any phase of treatment for whom kinetic data were available</population>
          <units>mg/kg/day</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
                <count group_id="O3" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.2" lower_limit="11" upper_limit="17"/>
                    <measurement group_id="O2" value="14.2" lower_limit="12" upper_limit="17"/>
                    <measurement group_id="O3" value="13.8" lower_limit="11" upper_limit="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis was that sequential addition of fibrate and niacin to baseline atorvastatin therapy would have no effect on apo-A1 production rates</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&gt;0.5</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Post-prandial Triglyceride Incremental Area Under the Curve (iAUC)</title>
        <description>Triglyceride iAUC was measured during an oral fat tolerance test administered after 4 weeks of atorvastatin 10 mg/day , a further 8 weeks of atorvastatin 10mg /day+ABT335 135mg/day and then after a further 10 weeks of atorvastatin 10 mg/day+ABT335 135 mg/day+Niaspan 2000 mg/day. The standardized oral fat load was administered one hour post medication dosing and blood was collected prior to drug dosing, prior to the oral fat load and hourly thereafter for 10 hours (0,1,2,3,4,5,6,7,8,9,10,12 hrs post drug dosing)</description>
        <time_frame>4 weeks, 12 weeks, 22 weeks</time_frame>
        <population>subjects completing any phase of treatment for whom complete post-prandial data were available</population>
        <group_list>
          <group group_id="O1">
            <title>Atorvastatin</title>
            <description>Subjects received atorvastatin 10 mg daily by mouth for 4 weeks followed by an oral fat tolerance test</description>
          </group>
          <group group_id="O2">
            <title>Atorvastatin+ABT335</title>
            <description>Subjects received atorvastatin 10 mg daily and ABT335 135 mg daily by mouth for 8 weeks followed by an oral fat tolerance test.</description>
          </group>
          <group group_id="O3">
            <title>Atorvastatin+ABT335+Niaspan</title>
            <description>Subjects received atorvastatin 10 mg daily, ABT335 135 mg and Niaspan 2000 mg daily by mouth for 10 weeks followed by an oral fat tolerance test.</description>
          </group>
        </group_list>
        <measure>
          <title>Post-prandial Triglyceride Incremental Area Under the Curve (iAUC)</title>
          <description>Triglyceride iAUC was measured during an oral fat tolerance test administered after 4 weeks of atorvastatin 10 mg/day , a further 8 weeks of atorvastatin 10mg /day+ABT335 135mg/day and then after a further 10 weeks of atorvastatin 10 mg/day+ABT335 135 mg/day+Niaspan 2000 mg/day. The standardized oral fat load was administered one hour post medication dosing and blood was collected prior to drug dosing, prior to the oral fat load and hourly thereafter for 10 hours (0,1,2,3,4,5,6,7,8,9,10,12 hrs post drug dosing)</description>
          <population>subjects completing any phase of treatment for whom complete post-prandial data were available</population>
          <units>mg/dl*h</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="770" lower_limit="618" upper_limit="921"/>
                    <measurement group_id="O2" value="515" lower_limit="361" upper_limit="670"/>
                    <measurement group_id="O3" value="381" lower_limit="214" upper_limit="547"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis was that sequential addition of fibrate and niacin to baseline atorvastatin therapy would have no effect on post-prandial triglyceride levels following an oral fat load</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0005</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0005</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>22 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Atorvastatin/ABT335/Niaspan</title>
          <description>Subjects received atorvastatin 10 mg/day for 4 weeks, followed by addition of ABT335 135 mg/day for a further 8 weeks followed by the addition of Niaspan 2000 mg/day for a further 10 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>4</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Richard Dunbar MD</name_or_title>
      <organization>University of Pennsylvania</organization>
      <phone>215-662-9024</phone>
      <email>richard.dunbar@uphs.upenn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

